|
1
|
Coward JI, Middleton K and Murphy F: New
perspectives on targeted therapy in ovarian cancer. Int J Womens
Health. 7:189–203. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Syrios J, Banerjee S and Kaye SB: Advanced
epithelial ovarian cancer: from standard chemotherapy to promising
molecular pathway targets - where are we now? Anticancer Res.
34:2069–2077. 2014.PubMed/NCBI
|
|
3
|
Landriscina M, Amoroso MR, Piscazzi A and
Esposito F: Heat shock proteins, cell survival and drug resistance:
the mitochondrial chaperone TRAP1, a potential novel target for
ovarian cancer therapy. Gynecol Oncol. 117:177–182. 2010.
View Article : Google Scholar
|
|
4
|
Chen YF, Dong Z, Xia Y, Tang J, Peng L,
Wang S and Lai D: Nucleoside analog inhibits microRNA-214 through
targeting heat-shock factor 1 in human epithelial ovarian cancer.
Cancer Sci. 104:1683–1689. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Anckar J and Sistonen L: Regulation of
HSF1 function in the heat stress response: implications in aging
and disease. Annu Rev Biochem. 80:1089–1115. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Vihervaara A and Sistonen L: HSF1 at a
glance. J Cell Sci. 127:261–266. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mendillo ML, Santagata S, Koeva M, Bell
GW, Hu R, Tamimi RM, Fraenkel E, Ince TA, Whitesell L and Lindquist
S: HSF1 drives a transcriptional program distinct from heat shock
to support highly malignant human cancers. Cell. 150:549–562. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Home T, Jensen RA and Rao R: Heat shock
factor 1 in protein homeostasis and oncogenic signal integration.
Cancer Res. 75:907–912. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dai C, Whitesell L, Rogers AB and
Lindquist S: Heat shock factor 1 is a powerful multifaceted
modifier of carcinogenesis. Cell. 130:1005–1018. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Calderwood SK: HSF1, a versatile factor in
tumorogenesis. Curr Mol Med. 12:1102–1107. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ciocca DR, Arrigo AP and Calderwood SK:
Heat shock proteins and heat shock factor 1 in carcinogenesis and
tumor development: an update. Arch Toxicol. 87:19–48. 2013.
View Article : Google Scholar
|
|
12
|
Meng L, Gabai VL and Sherman MY:
Heat-shock transcription factor HSF1 has a critical role in human
epidermal growth factor receptor-2-induced cellular transformation
and tumorigenesis. Oncogene. 29:5204–5213. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Santagata S, Hu R, Lin NU, Mendillo ML,
Collins LC, Hankinson SE, Schnitt SJ, Whitesell L, Tamimi RM,
Lindquist S, et al: High levels of nuclear heat-shock factor 1
(HSF1) are associated with poor prognosis in breast cancer. Proc
Natl Acad Sci USA. 108:18378–18383. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jin X, Moskophidis D and Mivechi NF: Heat
shock transcription factor 1 is a key determinant of HCC
development by regulating hepatic steatosis and metabolic syndrome.
Cell Metab. 14:91–103. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fang F, Chang R and Yang L: Heat shock
factor 1 promotes invasion and metastasis of hepatocellular
carcinoma in vitro and in vivo. Cancer. 118:1782–1794. 2012.
View Article : Google Scholar
|
|
16
|
Li Y, Xu D, Bao C, Zhang Y, Chen D, Zhao
F, Ding J, Liang L, Wang Q, Liu L, et al: MicroRNA-135b, a HSF1
target, promotes tumor invasion and metastasis by regulating RECK
and EVI5 in hepatocellular carcinoma. Oncotarget. 6:2421–2433.
2015. View Article : Google Scholar :
|
|
17
|
Santagata S, Mendillo ML, Tang YC,
Subramanian A, Perley CC, Roche SP, Wong B, Narayan R, Kwon H,
Koeva M, et al: Tight coordination of protein translation and HSF1
activation supports the anabolic malignant state. Science.
341:12383032013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Scherz-Shouval R, Santagata S, Mendillo
ML, Sholl LM, Ben-Aharon I, Beck AH, Dias-Santagata D, Koeva M,
Stemmer SM, Whitesell L, et al: The reprogramming of tumor stroma
by HSF1 is a potent enabler of malignancy. Cell. 158:564–578. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Dai C and Sampson SB: HSF1: guardian of
proteostasis in cancer. Trends Cell Biol. 26:17–28. 2016.
View Article : Google Scholar :
|
|
20
|
Whitesell L and Lindquist S: Inhibiting
the transcription factor HSF1 as an anticancer strategy. Expert
Opin Ther Targets. 13:469–478. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kumar S, Tomar MS and Acharya A:
HSF1-mediated regulation of tumor cell apoptosis: a novel target
for cancer therapeutics. Future Oncol. 9:1573–1586. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen Y, Chen J, Loo A, Jaeger S,
Bagdasarian L, Yu J, Chung F, Korn J, Ruddy D, Guo R, et al:
Targeting HSF1 sensitizes cancer cells to HSP90 inhibition.
Oncotarget. 4:816–829. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rossi A, Ciafrè S, Balsamo M, Pierimarchi
P and Santoro MG: Targeting the heat shock factor 1 by RNA
interference: a potent tool to enhance hyperthermochemotherapy
efficacy in cervical cancer. Cancer Res. 66:7678–7685. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chen YF, Dong Z, Jiang L, Lai D and Guo L:
Mouse primed embryonic stem cells could be maintained and
reprogrammed on human amnion epithelial cells. Stem Cells Dev.
22:320–329. 2013. View Article : Google Scholar
|
|
25
|
Agarwal T, Annamalai N, Khursheed A, Maiti
TK, Arsad HB and Siddiqui MH: Molecular docking and dynamic
simulation evaluation of Rohinitib - Cantharidin based novel HSF1
inhibitors for cancer therapy. J Mol Graph Model. 61:141–149. 2015.
View Article : Google Scholar : PubMed/NCBI
|
